Logo Image
|Articles|October 10, 2013

CHD Bioscience Developing New Class of Antimicrobial Products to Combat HAIs

CHD Bioscience, a development-stage life science company, is working to help commercialize a family of new broad-spectrum antimicrobial products that have the ability to safely eliminate a wide range of bacteria, viruses and other pathogens without causing undue harm to healthy cells or tissues.
 
Infections are becoming more widespread in our society, and nowhere is this more evident than in healthcare facilities, says Michael K. Handley, chief executive officer for CHD Bioscience.  Our company is committed to improving patients lives by bringing innovation from the laboratory into real products and services that can address the growing demand to eradicate the pathogens that lead to the spread of infection.
 
VERIOX, CHD Biosciences lead product, has demonstrated unique safety and efficacy properties (both in vitro and in vivo) that can help mitigate the increasing threat of HAIs, including treating infections from the most resistant bacterial strains, such as methicillin-resistant Staphylococcus aureus (MRSA), C. difficile spores and Carbapenem-Resistant Enterobacteriaceae (CRE). VERIOX is being developed for a wide variety of applications, including medical device disinfection and sterilization, surface disinfection, device coatings, hand sanitization and potential treatments for human/veterinary wound care.
 
Recently, preliminary independent testing conducted by ATS Labs in Minnesota has  demonstrated

VERIOX to be effective against destroying CRE bacteria on hard inanimate surfaces in as little as 1 minute. Testing confirmed that the antibiotic resistance profile of the organism tested was Carbapenem-Resistant Enterobacteriaceae. Additional testing following Good Laboratory Practices (GLP) will need to be conducted to support product registration and claims substantiation with the Environmental Protection Agency (EPA). 
 
Results of the ATS Labs study using VERIOX demonstrated the novelty of our experimental product as it completely and rapidly destroyed all the deadly CRE bacteria, said Mr. Handley.  These outcomes provide a significant step forward in the control of resistant pathogens.
 
CHD Bioscience is engaging in licensing opportunities with large multinational healthcare companies to bring these innovative antimicrobial products to market.
 
Source: CHD Bioscience

Related to this article

View more
Infection preventionists in full PPE with children in DRC. (Image credit: author with AI)
Chasing the Bundibugyo Outbreak: How Static Numbers Hide a Moving Epidemic
Nearly 4 months into the DRC's Bundibugyo virus disease outbreak, some indicators suggest transmission may be slowing. But shifting hotspots, treatment-center capacity problems, community deaths, and incomplete surveillance data show why national case totals alone cannot determine whether containment has been achieved.
Read more
Dyan Troxell, MSN, RN, director of clinical education at HandCraft Linen Services; J.J. Odom, MBA, CHESP, CMIP, T-CHEST, university director of buildings and grounds for UConn Health and chair-elect of the AHE Board; and Jenna Rivers, MPH, CPH, CIC, manager of infection prevention and control at Moffitt Cancer Center in Tampa, Florida.
At AHE Exchange26: Building Safer, Smarter Reusable Linen Programs
At AHE Exchange 2026, ICT spoke with experts representing commercial laundry services, EVS, and infection prevention about the systems behind a successful reusable linen program. They discuss linen quality, reject rates, unnecessary waste, frontline education, data, PAR levels, infection prevention oversight, and why strong relationships between health care facilities and their laundry providers matter.
Read more